NexMed, Inc. a specialty CRO with a pipeline of products based on the NexACT technology, announced the expansion of its senior business development team within NexMed (U.S.A.), with the appointments of Linda Smibert as Vice President of Business Development and Mark S. Wilson ('89) as Vice-President of Technology Development.
In his new position, Wilson is responsible for the out-licensing of the NexACT technology. Wilson brings to NexMed over 20 years of experience in the biopharmaceutical, diagnostic and medical device industries. Prior to joining NexMed, he was Entrepreneur-in-Residence at CONNECT in San Diego, where he provided business start-up strategy, development and sourcing consulting services to local companies. Prior to that, he served for five years as Vice President of Business Development at Halozyme Therapeutics, where, among others, he was responsible for initiating the company's $612 million alliance with F. Hoffmann-La Roche and for various alliances with Baxter Healthcare. Wilson earned a B.S. in Mechanical Engineering from the University of California, Berkeley, and an MBA from UCLA Anderson.
Commenting on today's news, Bassam Damaj, Ph.D., President and Chief Executive Officer of NexMed, stated, "We are very pleased to welcome both Linda and Mark to NexMed at this critical stage in our corporate development. Our stated goal is to actively pursue key partnership opportunities for both our NexACT technology and pipeline products. Given the increasing number of licensing inquiries that we have received, these two highly regarded business development executives will play a key role in our growth going forward, leveraging their expertise and strong industry relationships to broaden the Company's visibility and partnership opportunities in 2010 and beyond."<< More News